PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of current protocol is try improve the results of chemotherapy treatment in patients with ALL wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by re-inductions.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: 6-Mercaptopurine; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Mercaptopurine; Methotrexate; Prednisone; Vincristine

Criteria

Inclusion Criteria:

• Adults (over 15 years) with ALL standard risk no prior antiblastic chemotherapy

Exclusion Criteria:

• Mature B-ALL (FABL3) or with cytogenetic ALL "Burkitt-like" alterations (t[8;14], t[2;8], t[8;22])

• Mixed forms of ALL

• Acute Leukemia no differentiate

• Patients with coronary disorders, valvular or hypertensive cardiopathy

• Patients with chronic liver disorders

• Chronic pulmonary disorders

• Renal insufficiency

• Neurologic disfunctions

• ECOG 3 and 4

• No signed consent form